You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 輔助生殖概念股走強 多隻個股漲停
格隆匯1月28日丨輔助生殖概念股走強,悦心健康、奧鋭特漲停,潔特生物、昌紅科技、達嘉維康、亞輝龍等跟漲,近期,國家衞健委在官網公佈了《關於政協十三屆全國委員會第四次會議第4201號提案答覆的函》。國家衞健委在這份《關於禁止地下“商業買賣卵子”的提案》答覆函中提到,要建立健全合法捐卵、儲卵途徑。 國家衞健委近期已啟動對輔助生殖技術相關管理辦法、基本標準和技術規範等的修訂工作,進一步明確和完善相關工作要求和技術流程,規範輔助生殖技術的應用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.